Apple Podcastsで聴く Spotifyで番組を探す AmazonMusicで探す Googleで番組を探す

WEEKLY PICKUP!!

古着思考　~古着好きの, 古着好きによる, 古着好きのためのRADIO - 是永幸亮

「古着」について様々な視点から発信しているポッドキャスト。スウェットを例に古着の魅力が分解・解説されている「#4 ネクストビンテージとは...？？」は、古着に興味を持ち始めたあなたにおすすめ。
郷土芸能かしましラジオ - 郷土芸能かしましラジオ

郷土芸能の有識者へのインタビューが通じて知識理解を深めるポッドキャスト。郷土芸能について全く知らなくても、その魅力が分かるやさしい構成なのでスキマ時間のインプットに最適。
福田さん!どうしてKATANAに乗らないの!? - J-WAVE

バイク好き芸人・チュートリアル福田が、スズキが製造する名車「KATANA」の魅力について、KATANAユーザーやスズキの社員と語り合うポッドキャスト。
Sponsored

Adobe Experience Cloud ポッドキャスト - アドビ株式会社

デジタルマーケティングの第一線で活躍するゲストを迎え、顧客体験のあり方を考える対談シリーズ『Marketer’s Talk』。ゲストが語るリアルな課題や日々の気づきを通じて、顧客体験管理への理解を深める"マーケター同士のオフ会トーク"ポッドキャスト。

Project Advocacy 医学

Kidney Transplant Conversations - Project Advocacy

Kidney Transplant Conversations features diverse voices and experiences of donating, receiving, and caring for this gift of life. Over the coming months each new episode will feature interviews with patients, caregivers, advocates, donors, healthcare providers, and community leaders.

At its highest level, our podcast series focuses on quality healthcare delivery, highlighting the innovative approaches kidney transplant recipients and providers are applying to improve care. Along the way, we’ll explore all the stages of the kidney transplant journey and invite our guests to share their experiences and insights. We’ll also look at things like health disparities in renal transplant, identifying where and why some groups don’t do as well when compared to others, and discuss what we can do to close the gap. This will include explorations of inclusion, diversity, equity and access (also known by the acronym IDEA), which are all subjects central to the purpose of this podcast. We invite you to subscribe and let Kidney Transplant Conversations keep you connected, informed and inspired with a constant flow of new thoughts and ideas.

Kidney Transplant Conversations is underwritten by Veloxis Pharmaceuticals, Inc. All views and opinions expressed in the podcast reflect those of the participants and do not necessarily represent the views and opinions of Veloxis Pharmaceuticals, Inc.